首页> 美国卫生研究院文献>Springer Open Choice >Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents

【2h】

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents

机译：评价抗药抗体对CT-P13和英夫利昔单抗参比药物（Remicade）的交叉反应性：使用两种试剂标记的免疫分析方法进行的分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundDuring two pivotal clinical trials of the infliximab biosimilar CT-P13 (PLANETAS and PLANETRA), antidrug antibodies (ADAs) and neutralising antibodies (NAbs) were detected in the sera of patients treated with CT-P13 and the reference product (RP; Remicade).

机译：背景在英夫利昔单抗生物仿制药CT-P13的两项关键临床试验（PLANETAS和PLANETRA）中，在用CT-P13和参考产品（RP; Remicade）治疗的患者血清中检测到抗药物抗体（ADAs）和中和抗体（NAbs）。。

著录项

期刊名称 Springer Open Choice
作者
Walter Reinisch; Jørgen Jahnsen; Stefan Schreiber; Silvio Danese; Julián Panés; Alejandro Balsa; Won Park; JiSoo Kim; Jee Un Lee; Dae Hyun Yoo;
展开▼
作者单位

展开▼
年(卷),期 -1(31),3
年度 -1
页码 223–237
总页数 15
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents [J] . Reinisch Walter, Jahnsen Jorgen, Schreiber Stefan, BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2017,第3期

机译：评估抗抗皱抗体对CT-P13和英夫利昔单抗的交叉反应性（Remicade）：使用ImmunoAssays用两个药剂标记的分析
2. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [J] . Yoo Dae Hyun, Prodanovic Nenad, Jaworski Janusz, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第2期

机译：CT-P13（BioSimilarIngiximab）在类风湿性关节炎患者中的功效和安全性：从Planetra延伸研究中的CT-P13切换到CT-P13的切换与Planetra延伸研究中的持续CT-P13的比较
3. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data [J] . Expert opinion on biological therapy . 2015,第12期

机译：在患有风湿病的患者中，将CT-P13（英夫利昔单抗生物仿制药）从雷米卡德（英夫利昔单抗）转换为临床有效性。基于前瞻性观察数据的临床经验报告
4. IN-HOUSE DEVELOPMENT AND CROSS-REACTIVITY EVALUATION OF A POLYCLONAL ANTIBODY FOR THE IMMUNOANALYSIS OF THE POLLUTANT 2,4,6-TRICHLOROPHENOL [C] . NIKOLAKI E, VASSILAKOPOULOU V, KARACHALIOU C.E International Conference on Environmental Science and Technology . 2015

机译：对污染物2,4,6-三氯苯酚免疫分析的多克隆抗体的内部开发和交叉反应性评价
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Extended report: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [O] . Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, -1

机译：扩展报告：类风湿关节炎患者中CT-P13（生物仿制药英夫利昔单抗）的疗效和安全性：在PLANETRA扩展研究中从参考英夫利昔单抗转换为CT-P13与持续进行CT-P13之间的比较
7. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product [O] . ??? 2015

机译：生物仿制药英夫利昔单抗（CT-p13）的临床试验分析及英夫利昔单抗参考药品的历史临床研究比较
8. Extensive Antibody Cross-reactivity among Infectious Gram-negative Bacteria Revealed by Proteome Microarray Analysis [R] . Keasey, S. L., Schmid, K. E., Lee, M. S., 2009

机译：通过蛋白质组微阵列分析揭示的传染性革兰氏阴性细菌之间广泛的抗体交叉反应性

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅